The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

BACKGROUND: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free TNF inhibitor certolizumab pegol (CZP) on AAU flares in patients with active axSpA at high risk of recurrent AAU....

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:RMD Open
Huvudupphovsmän: van der Horst-Bruinsma, Irene, van Bentum, Rianne, Verbraak, Frank D, Rath, Thomas, Rosenbaum, James T, Misterska-Skora, Maria, Hoepken, Bengt, Irvin-Sellers, Oscar, VanLunen, Brenda, Bauer, Lars, Rudwaleit, Martin
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2020
Ämnen:
Spondyloarthritis
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299504/
https://ncbi.nlm.nih.gov/pubmed/32371433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2019-001161
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk